Anika’s Orthovisc
This article was originally published in The Gray Sheet
Executive Summary
J&J Ortho Biotech will launch the injectable hyaluronic acid product for knee osteoarthritis pain in the U.S. following PMA approval, announced Feb. 5. Maker Anika Therapeutics will receive a $20 mil. milestone payment this quarter under a December domestic marketing agreement. Anika estimates the U.S. viscosupplementation market at $350 mil. J&J plans a launch "over the next few months" after a roll-out at the March 10-14 American Academy of Orthopaedic Surgeons meeting in San Francisco. Orthovisc has been available internationally since 1996. An initial PMA was rejected by FDA in 1998, leading to two additional studies and a revised PMA (1"The Gray Sheet" June 9, 2003, p. 27). Competitors include Genzyme Biosurgery's Synvisc, Smith & Nephew's Supartz and Fidia Pharmaceuticals' Hyalgan...
You may also be interested in...
Orthovisc Clinical Trial Data Filed With FDA; Will Third Time Prove A Charm?
Anika Therapeutics will seek a marketing partner to distribute its Orthovisc injectable hyaluronic acid if the knee osteoarthritis therapy is approved by FDA
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.